Strategies for pneumococcal vaccination in older adults in the coming era

Figures & data

Table 1. Summary of PPSV23 efficacy and effectiveness, and non-PCV13 and non-PPSV23 serotypes of pneumococcal pneumonia in the older population in Japan, with condition of pediatric PCV vaccination.

Ref	Study period	Condition of pediatric PCV vaccination	Study design	VE (95%CI) for all-cause pneumonia	VE (95%CI) for pneumococcal pneumonia	Non-PCV13 and non-PPSV23 serotypes of pneumococcal pneumonia in older population
Kawakami et al.^Citation19	2005–2007	Pre-PCV7	Randomized Controlled trial	41.5% (2.7 to 65.5) (in subjects over 75 years old) 62.7% (25.7 to 82.1) (in subjects with difficulty walking)	Not assessed	Proportion of non-PCV13 and non-PPSV23 serotypes 25% (2006)^Citation23,Citation24
Maruyama et al.^Citation20	2006–2009	Pre-PCV7	Randomized Controlled trial	44.8% (22.4 to 60.8)	63.8% (32.1 to 80.7)	Same as above
Suzuki K et al.^Citation21	2010–2014	Post-PCV7, Pre-PCV13	Case-control study	No effectiveness (24% [−32 to 66])	77% (34 to 92)	Proportion of non-PCV13 and non-PPSV23 serotypes 28% (2011– 2014)^Citation26
Suzuki M et al.^Citation22	2011–2014	Post-PCV7, Pre-PCV13	Case-control study (Test-negative design)	Not assessed	27.4% (3.2 to 45.6)	Same as above
Nakashima et al.^Citation15	2016–2019	Post-PCV13	Case-control study	No effectiveness (−33% [−109 to 15])	No effectiveness (7% [−150 to 65])	Proportion of non-PCV13 and non-PPSV23 serotypes 49% (2016–2017)^Citation26

Abbreviations: PCV, pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine; PCV7, 7-valent pneumococcal conjugate vaccine; VE, vaccine efficacy/effectiveness; PCV13, 13-valent pneumococcal conjugate vaccine.

Kawakami K, Ohkusa Y, Kuroki R, Tanaka T, Koyama K, Harada Y, Iwanaga K, Yamaryo T, Oishi K. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine. 2010;28:7063–9. doi:10.1016/j.vaccine.2010.08.010.

 PubMed Web of Science ®Google Scholar

Shoji H, Maeda M, Shirakura T, Takuma T, Hanaki H, Niki Y. Changes in the distribution of capsular serotypes of streptococcus pneumoniae isolated from adult respiratory specimens in Japan. Intern Med. 2015;54(11):1337–41. doi:10.2169/internalmedicine.54.3845.

 PubMed Web of Science ®Google Scholar

Katoh S, Suzuki M, Ariyoshi K, Morimoto K. Serotype replacement in adult pneumococcal pneumonia after the introduction of seven-valent pneumococcal conjugate vaccines for children in Japan: a systematic literature review and pooled data analysis. Jpn J Infect Dis. 2017;70(5):495–501. doi:10.7883/yoken.JJID.2016.311.

 PubMed Web of Science ®Google Scholar

Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, D’Alessandro-Gabazza C, Nakayama S, Nishikubo K, Noguchi T, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ (Clin Res Ed). 2010;340(mar08 1):c1004–c. doi:10.1136/bmj.c1004.

 PubMedGoogle Scholar

Suzuki K, Kondo K, Washio M, Nakashima K, Kan S, Imai S, Yoshimura K, Ota C, Ohfuji S, Fukushima W, et al. Preventive effects of pneumococcal and influenza vaccines on community-acquired pneumonia in older individuals in Japan: a case-control study. Hum Vaccines Immunother. 2019;15(9):2171–7. doi:10.1080/21645515.2019.1584023.

 PubMed Web of Science ®Google Scholar

Sando E, Suzuki M, Furumoto A, Asoh N, Yaegashi M, Aoshima M, Ishida M, Hamaguchi S, Otsuka Y, Morimoto K, et al. Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: the Japan Pneumococcal Vaccine Effectiveness study (J-PAVE). Vaccine. 2019;37(20):2687–93. doi:10.1016/j.vaccine.2019.04.009.

 PubMed Web of Science ®Google Scholar

Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, Ishida M, Hamaguchi S, Aoshima M, Ariyoshi K, et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis. 2017;17(3):313–21. doi:10.1016/S1473-3099(17)30049-X.

 PubMed Web of Science ®Google Scholar

Nakashima K, Suzuki K, Aoshima M, Murabata M, Kondo K, Ohfuji S, Fukushima W, Maeda A, Hirota Y. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: a multicenter hospital-based case-control study in Japan. Vaccine. 2022;40:6589–98. doi:10.1016/j.vaccine.2022.09.055.

 PubMed Web of Science ®Google Scholar